RecruitingPhase 3NCT05125302
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Sponsor: AbbVie
Anaheim, CA · Fresno, CA · La Palma, CA · +122 more sites